Bioptimus Names Julie Gerardi as Chief Commercial Officer to Accelerate AI-Driven Biological Discovery
Bioptimus, the Paris-based AI company developing the first universal foundation model for biology, has appointed biotech industry veteran Julie Gerardi as Chief Commercial Officer (CCO). With over 25 years of experience across startups and Fortune 500 life sciences firms, Gerardi will lead Bioptimus’s commercial strategy as it scales its groundbreaking work in biological modeling.
Gerardi brings a unique blend of scientific training and commercial expertise to the role. A biochemist by background, she has led commercial and business development teams at the forefront of biomedical innovation. Most recently, she served as Vice President of Business Development and Strategy at Parse Biosciences, a company specializing in scalable single-cell sequencing technologies that support foundational biological datasets. Prior to that, she was VP of Business Development at Tempus AI, where she drove commercial efforts across biological modeling and tumor organoid platforms.
In her new position, Gerardi will focus on strengthening Bioptimus’s strategic partnerships within pharma and biological research, while executing go-to-market strategies for the company’s AI-based solutions. Her appointment marks a pivotal step for Bioptimus as it moves to commercialize its proprietary models and data infrastructure.
"I am proud and humbled to join the incredible team at Bioptimus," said Gerardi. "The opportunity to help build foundation models that reveal the hidden architecture of life—from cells to complex systems—is truly inspiring. H-Optimus-1, trained on billions of high-quality data points, is unlocking patterns that were previously out of reach. That’s the kind of innovation I’m excited to scale."
David Cahané, Bioptimus General Manager and Co-Founder, emphasized the strategic importance of the appointment: "Julie’s proven ability to translate advanced biological technologies into commercial success makes her an ideal fit for our next phase of growth. Her belief in the transformative power of generative AI aligns perfectly with our mission to drive breakthroughs in biomedical research and patient care."
Founded in 2023 by leaders from Google DeepMind, Owkin, and Novartis, Bioptimus is building the world’s first multi-scale foundation model for biology. By combining large-scale artificial intelligence with proprietary biological datasets, the company aims to decode the complexity of life and accelerate biomedical innovation.
Learn more at www.bioptimus.com